

1 Dalmore Drive,  
Scoresby,  
Victoria 3179  
AUSTRALIA  
T: +61 (0)3 9763-1287  
F: +61 (0)3 9763-2817  
[www.generabiosystems.com](http://www.generabiosystems.com)

**Monday 2 July 2018**

**ASX Announcement – GENERA BIOSYSTEMS LIMITED (ASX: GBI)  
GENERA – CAPITAL STRUCTURE UPDATE**

---

Genera wishes to inform the market that it will not be seeking an additional extension to the Series B Notes that were due for redemption on 30 June 2018, having been extended from an original redemption date of December 2016. It is the current intention of the Board to shortly undertake a capital raising to refinance the Series B Notes.

Since the 8 May announcement of Genera's Distribution Agreement with Beckman Coulter Life Sciences, Genera has been engaged with a number of institutional investors exploring support for a capital raising that will strengthen the Company's financial position and support the planned rollout of Genera's test menu operating on the new automated Beckman Coulter system.

In addition to the proposed financing, Genera continues to engage with a well-credentialed trade related party involving a jurisdictional licensing of PapType® for China and potentially other selected markets excluding the Australian, New Zealand, US and Canadian markets. Any completed licensing transaction shall involve an upfront license fee payment that may further strengthen Genera's financial position and support the commercial roll-out of Genera's valuable AmpaSand® test menu running on the new Beckman Coulter system.

---

For further information please contact:

Mr Richard Hannebery  
Chief Executive Officer  
Genera Biosystems Limited  
Telephone: +61 (0)3 9763 1287  
[www.generabiosystems.com.au](http://www.generabiosystems.com.au)

**About Genera Biosystems** : Genera Biosystems Limited (“GBI”) is an Australian Securities Exchange listed molecular diagnostics company, which develops, manufactures and distributes advanced PCR molecular diagnostics tests.

Genera’s single-well high multiplex AmpaSand® testing platform can detect up to 125 target analytes in a single-well of a reaction plate. Unlike traditional real-time PCR approaches, AmpaSand® single-well multiplex tests when run on a seamlessly integrated flow cytometry and liquid handling system can provide unparalleled throughput capability and cost efficiency for high volume pathology laboratories qualitative molecular testing needs.<sup>1</sup>

Genera manufactures products in its Australian Therapeutics Goods Administration certified manufacturing facility in Scoresby, Victoria, Australia.

PapType®, an ARTG listed and CE-marked MDx test, simultaneously detects and identifies 14 high-risk types of HPV and 2 low risk HPV types in a single-well. These high-risk HPV types are responsible for 99.7% of all cases of cervical cancer.

In addition to PapType®, Genera has also commercialized and gained ARTG listing and CE mark for RTIplex™, a single-well multiplex MDx that identifies 15 common upper respiratory tract pathogens, including Influenza A & B, as well as 10 other viral and 3 bacterial disease-causing microbial targets.

Genera’s development pipeline includes a new 8-plex sexually transmitted infections panel that is expected to be available in the 2<sup>nd</sup> half of 2018, with plans to broaden the AmpaSand® test menu further to 6 highly competitive single-well multiplex MDx assays by 2019.

PapType®, RTIplex™, and the tests in development, employ the AmpaSand® biochemistry as well as Genera’s proprietary ARTG listed and CE-IVD marked QPlots™ automated analytical and reporting software that is compatible with most Laboratory Information Management Systems (‘LIMS’).

All the components of the Genera MDx system, including AmpaSand® and QPlots™, have been optimized to run on Beckman Coulter’s innovative CytoFLEX™ flow cytometry system.

---

<sup>1</sup> All ‘plate based’ Real Time PCR platforms can ‘multiplex’ up to 4 targets per well assuming 4 available channels of a Real Time PCR instrument. To multiplex greater than 4 target analytes in a test most platforms require use of additional wells of a plate to test for the additional target analytes. As such commercially, their multiplexing capability is restricted due to a direct trade-off with volume throughput per plate (96 or 384 well). Genera’s AmpaSand® technology facilitates the multiplexing of up to ~125 target analytes **in a single-well** of a plate. On a like for like basis depending on the number of target analytes detected in a multiplex assay Genera’s AmpaSand® technology facilitates > 4X relative volume throughput. High volume throughput is a key commercial consideration for all large pathology labs undertaking HPV and STI testing.